G1 Therapeutics.jpg
Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer
January 14, 2020 07:00 ET | G1 Therapeutics
SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a...
G1 Therapeutics.jpg
G1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
January 07, 2020 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics.jpg
G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)
December 11, 2019 18:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase...
G1 Therapeutics.jpg
G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019
November 26, 2019 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics.jpg
G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019
November 12, 2019 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics.jpg
G1 Therapeutics Provides Third Quarter 2019 Corporate and Financial Update
November 05, 2019 16:00 ET | G1 Therapeutics
Company to complete New Drug Application (NDA) submission for trilaciclib in small cell lung cancer in 2Q20 Phase 2 trilaciclib data and Phase 1 G1T48 data presented at ESMO Management to host webcast...
G1 Therapeutics.jpg
G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019
October 29, 2019 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
G1 Therapeutics.jpg
G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019
September 29, 2019 06:00 ET | G1 Therapeutics
-- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1...
G1 Therapeutics.jpg
G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival
September 28, 2019 04:15 ET | G1 Therapeutics
-- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung...
G1 Therapeutics.jpg
G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress
September 10, 2019 06:01 ET | G1 Therapeutics
-  Company to present first clinical data on oral SERD G1T48 in breast cancer - - Overall survival data on trilaciclib in women with metastatic triple-negative breast cancer (mTNBC) accepted for...